摘要
索拉非尼作为多靶点、多激酶抑制剂,经国际大型临床研究证实可以延长晚期肝细胞癌患者的生存期,其疗效和安全性较好,但也存在一些不足之处。为了进一步合理用药并提高患者疗效,我国学者开展了采用索拉非尼单药治疗或联合其他方案治疗晚期肝细胞癌的临床试验研究。本文拟对近年我国相关研究进行介绍。
Sorafenib is a multi-targeted, multi-kinase inhibitor, which has been proved to prolong the survival of patients with advanced hepatocellular carcinoma by large- scale, international clinical studies. Sorafenib has been demonstrated its good efficacy and safety. However, there are many shortcomings of it. The domestic scholars have carried out many clinical studies of sorafenib monotherapy or combined therapy with other regimens in the treatment of advanced hepatocellular carcinoma. This paper reviewed and introduced these related studies.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2016年第1期5-11,共7页
Chinese Journal of New Drugs and Clinical Remedies
关键词
索拉非尼
癌
肝细胞
受体蛋白质酪氨酸激酶类
sorafenib
carcinoma, hepatocellular
receptor protein-tyrosine kinases
